血清肿瘤标志物对肺癌患者支气管镜活检病理组织学分型的预测价值

doi:10.11904/j.issn.1002-3070.2022.04.005

Abstract

Abstract: Objective The aim of the study was to investigate the relationship between the serum levels of tumor markers and histopathological types of bronchoscopy biopsy.Methods A retrospective study was performed in 356 lung cancer patients who underwent bronchoscopy biopsy at Harbin Medical University Cancer Hospital from January 2013 to December 2018 and completed the detection of related serum tumor markers(SCCA,CYFRA21-1,CEA,CA125 and NSE).Patients with lung cancer(140 small cell carcinoma,122 squamous cell carcinoma and 94 adenocarcinoma)were retrospectively analyzed.Results In lung cancer patients with bronchoscopy biopsy,the combination of five serum tumor markers(SCCA+CYFRA21-1+CEA+CA125+NSE,AUC=0.948,P＜0.001)had a high value in assisting the diagnosis of small cell carcinoma and non-small cell lung cancer;three(SCC+CEA+ NSE,AUC=0.901,P＜0.001)or four(SCC+CYFRA21-1+CEA+NSE,AUC=0.901,P＜0.001)markers combined to distinguish squamous cell carcinoma and adenocarcinoma were more accurate.The value of the three marker combination(SCCA+CEA+CA125,AUC=0.831,P＜0.001)had a high value of diagnosis.Conclusion For lung cancer patients with different pathological types,the combination of different serum tumor markers has certain auxiliary diagnostic value for pathological types under bronchoscopy biopsy.

Key words: Lung cancer, Tumor markers, Bronchoscopy, Biopsy pathology

CLC Number:

R734

SUN Weiling, ZHANG Minghui, WU Huaxing, ZHAO Yanbin. Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer[J]. Journal of Practical Oncology, 2022, 36(4): 316-322.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.04.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I4/316

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 中华人民共和国国家卫生健康委员会.常见肿瘤诊疗指南(2022版)[S].原发性肺癌诊疗指南,2022,74.
3 Ferrigno D,Buccheri G,Biggi A.Serum tumour markers in lung cancer:history,biology and clinical applications[J].Eur Respir J,1994,7(1):186-197.
4 Kagohashi k,Satoh H,Ishikawa H,et al.Are-evaluation of squamous cell carcinoma antigen(SCC)as a serum marker for non-small cell lung cancer[J].Med Oncol,2008,25(2):187-189.
5 van der Gaast A,Schoenmakers CH,Kok TC,et al.Evaluation of a new tumour marker in patients with non-small-cell lung cancer:Cyfra 21.1[J].Br J Cancer,1994,69(3):525-528.
6 Yan HJ,Wang RB,Zhu KL,et al.Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma[J].Chin Med J(Engl),2012,125(8):1410-1415.
7 Tahanovich AD,Kauhanka NN,Prohorova VI,et al.Predicting the risk of tumor progression in patients with early stages of adenocarcinoma and squamous cell lung carcinoma based on laboratory parameters[J].Biomed Khim,2021,67(6):507-517.
8 Hammarstrom S.The carcinoembryonic antigen(CEA)family:structures,suggested functions and expression in normal and malignant tissues[J].Semin Cancer Biol,1999,9(2):67-81.
9 Chen ZQ,Huang LS,Zhu B.Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer[J].Dis Markers,2018,2018:9845123.
10 Li Z,Zhao J.Clinical efficacy and safety of crizotinib and alectinib in ALK-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy[J].Am J Transl Res,2021,13(11):13108-13116.
11 Jørgensen LG,Osterlind K,Genollá J,et al.Serum neuron-specific enolase(S-NSE)and the prognosis in small-cell lung cancer(SCLC):a combined multivariable analysis on data from nine centres[J].Br J Cancer,1996,74(3):463-467.
12 Pastor A,Menéndez R,Cremades MJ,et al.Diagnostic value of SCC,CEA and CYFRA 21.1 in lung cancer:a Bayesian analysis[J].Eur Respir J,1997,10(3):603-609.
13 Tumour markers in lung cancer:EGTM recommendations.European Group on Tumour Markers[J].Anticancer Res,1999,19(4A):2817-2819.
14 Peladan F,Monteil H.Gas chromatographic study of volatile fatty acids produced by 14 species of Pseudomonas[J].Ann Microbiol(Paris),1984,135(3):399-410.
15 Xu LH,Su ZM,Xie BS.Diagnostic value of conventional tumor markers in young patients with pulmonary nodules[J].J Clin Lab Anal,2021,35(9):23912.
16 Robert CT,Haycock PC,Relton CL,et al.The causal relevance of body mass index in different histological types of lung cancer:A Mendelian randomization study[J].Sci Rep,2016,6:31121.
17 Doll R,Peto R.Cigarette smoking and bronchial carcinoma:dose and time relationships among regular smokers and lifelong non-smokers[J].J Epidemiol Community Health,1978,32(4):303-313.
18 Lee PN,Forey BA.Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review[J].BMC Cancer,2013,13:189.
19 Brooke T,Meredith G,Lisa WL,et al.Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool[J].Clin Lung Cancer,2013,14(2):108-112.
20 Seligson MT,Surowiec SM.Superior Vena Cava Syndrome,Essays in StatPearls[OL](Treasure Island(FL):StatPearls Publishing,2022).
21 Li JL,Chen YQ,Wang XD,et al.The value of combined detection of CEA,CYFRA21-1,SCC-Ag,and pro-GRP in the differential diagnosis of lung cancer[J].Transl Cancer Res,2021,10(4):1900-1906.
22 Wu H,Wang Q,Liu Q,et al.The serum tumor markers in combination for clinical diagnosis of lung cancer[J].Clin Lab,2020,66(3):10.
23 Mehta A,Parkash A,Bhatia M.Cross-sectional study to establish the utility of serum tumor markers in the diagnosis of lung cancer[J].Asian Pac J Cancer Prev,2021,22(8):2569-2576.
24 Ouyang RR,Wu SJ,Zhang B,et al.Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer[J].Cancer Biomark,2021,32(3):401-409.
25 Li Q,Sang S.Diagnostic value and clinical significance of combined detection of serum markers CYFRA21-1,SCC Ag,NSE,CEA and ProGRP in non-small cell lung carcinoma[J].Clin Lab,2020,66(11):10.

[1]	LI Xinlin, ZHOU Jinyi, HAN Renqiang, CAI Bo, XU Hong, HAN Yingying. Analysis of epidemiological characteristics of lung cancer in Nantong City from 2013 to 2017 [J]. Journal of Practical Oncology, 2022, 36(4): 304-309.
[2]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[3]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[4]	XIAO Haifan, YAN Shipeng, LI Jigang, SHI Zhaohui, ZOU Yanhua, XU Kekui, LIAO Xianzhen. Screening results and compliance analysis of low-dose spiral CT for lung cancer in Hunan from 2017 to 2018 [J]. Journal of Practical Oncology, 2022, 36(2): 99-104.
[5]	ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(1): 20-25.
[6]	LUO Wen, JIA Li, ZHANG Jiawen, WANG Dongjie, KONG Yingjun. The effects of circRNA MYO1C on lung cancer cell autophagy and cancer stem cell differentiation [J]. Journal of Practical Oncology, 2021, 35(6): 500-505.
[7]	WU Changshuai, ZHANG Baohui, GAO Zhenglian, ZHANG Xiaowang, WANG Kun. Research progress in anti-tumor effect of propofol and its molecular mechanism in lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 480-484.
[8]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[9]	REN Siying, CHEN Yang, SHI Qingping, ZHU Yunfang, WEN Hongmei. Characteristics of lung cancer incidence and mortality from 2011 to 2016 in the cancer registration areas of Yunnan province and its time trend [J]. Journal of Practical Oncology, 2021, 35(4): 332-338.
[10]	WEI Donghua, MA Yanling, ZHANG Juan, YIN Huiping, ZHANG Xiaopeng, ZHANG Yuhan, DAI Min, QIAN Liting. Analysis of lung cancer screening rate and screening results of urban residents in Hefei from 2014 to 2016 [J]. Journal of Practical Oncology, 2021, 35(3): 231-236.
[11]	WANG Junmei, PAN Huiqing, LI Jingyi, JIA Di, ZHAO Weiming, LV Changlian. The expression and clinical significance of MT2-MMP at the stage II of lung adenocarcinoma [J]. Journal of Practical Oncology, 2021, 35(3): 243-247.
[12]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.
[13]	JIAO Zhiyun, DU Fang, HE Ling, YUAN Baofeng. Preliminary study of dynamic contrast-enhanced magnetic resonance imaging in mediastinal lymph node metastasis of lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 142-147.
[14]	DONG Cheng,DUAN Yong. Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(1): 64-68.
[15]	BAO Yu,ZHU Lijian,QIAN Jiang. New progress in the research of anti-angiogenic drugs in the treatment of lung cancer with brain metastases [J]. Journal of Practical Oncology, 2021, 35(1): 91-96.

Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments